1.
Leuk Res Rep
; 19: 100360, 2023.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36590864
RESUMO
Despite widespread use of Pegylated forms of Inteferon in the management of Myeloproliferative Neoplasms (MPN), most clinicians have experience predominantly with peginterferon alfa-2a (Pegasys). Third generation pegylated IFNα, ropeginterferon alfa-2b (ropegIFN; Besremi), was recommended by the European Medicine Authority (EMA) for treatment of Polycythaemia Vera (PV) following a Phase III trial (PROUD-PV / CONTINUATION-PV). FDA approval for PV, regardless of treatment history, was subsequently granted in November 2021. We hereby demonstrate the safety and tolerability of ropegIFN in a series of MPN patients at variable doses. It corroborates reports of efficacy of ropegIFN in patients with PV and use in pregnancy.
2.
Br J Haematol
; 190(4): e248-e250, 2020 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32428243
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Tratamento Farmacológico da COVID-19 , COVID-19 , Leucemia Promielocítica Aguda , SARS-CoV-2 , Adulto , Trióxido de Arsênio/administração & dosagem , COVID-19/diagnóstico , Humanos , Leucemia Promielocítica Aguda/diagnóstico , Leucemia Promielocítica Aguda/tratamento farmacológico , Masculino , Tretinoína/administração & dosagem
3.
Hematology
; 20(3): 182-3, 2015 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25801784